Detailed explanation of the correct usage and dosage of macitentan

Macitentan (Macitentan) is an endothelin receptor antagonist (ERA), mainly used to treat pulmonary arterial hypertension (PAH) to delay disease progression and reduce the risk of hospitalization. Correct mastery of its usage and dosage is crucial to the patient's therapeutic effect and safety.

The recommended dose of macitentan is 10 mg taken orally once daily with or without food. This dose was determined based on the results of clinical trials and can effectively improve patients' symptoms of pulmonary hypertension while maintaining good safety. Patients should strictly follow the doctor's instructions, take the medicine on time and in the right amount, and should not adjust the dosage or stop taking the medicine on their own.

Patients should undergo liver enzyme testing before initiating macitentan therapy and retest as clinically appropriate during treatment. This is because macitentan may cause increases in liver enzymes and even cause hepatotoxicity. If the liver enzymes increase more than 3 times the upper limit of normal, use of this product should be discontinued. In addition, for patients with liver damage, it should be used with caution and the dosage should be adjusted under the guidance of a doctor.

Special groups such as women of childbearing age should rule out pregnancy before starting treatment, ensure the use of reliable contraceptive measures, and conduct a pregnancy test once a month during treatment. Because macitentan may cause damage to the fetus when used during pregnancy, it is contraindicated in pregnant women. In patients with renal impairment, renal function and serum potassium levels should be closely monitored, although dose adjustment is not necessary.

While using macitentan, patients should also pay attention to possible adverse reactions, such as anemia, nasopharyngitis, bronchitis, headache, etc. If serious adverse reactions occur, seek medical attention promptly. At the same time, attention should be paid to the interaction between macitentan and other drugs. For example, when used in combination with a strong inducer or inhibitor of CYP3A4, its efficacy and safety may be affected.

When using macitentan, patients should strictly follow the doctor's instructions, master the correct usage and dosage, and pay close attention to the body's reaction to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.opsumit.com/

xa0